Stock Analiz

Innate Pharma SA IPHA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$1.38Market cap $154M
Open the interactive analysis →

Innate Pharma SA (IPHA) is a healthcare company listed in the US with a market value of about $154M. In the twelve months to June 30, 2026 it had revenue of $5M and net income of -$52M, a net margin of -1121.6%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -34% a year, a 5-year average ROIC of -190%.

About Innate Pharma SA

Innate Pharma SA is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $53M in 2017 to $11M in 2025, a decline of about 18.2% a year. It was profitable in 1 of the last 9 years in our data.

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S14.3
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-49.4%
Revenue growth (5 yrs, per year)-34.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-223.8%
ROIC (5-yr avg.)-189.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$5M$11M$21M$68M$62M$28M$86M$96M$108M$53M
Net income-$52M-$58M-$51M-$8M-$62M-$60M-$79M-$23M$3M-$58M
Free cash flow-$27M-$62M-$8M-$36M-$21M-$67M-$65M$38M-$38M-$61M
EPS (diluted)$-0.56$-0.52$-0.46$-0.07$-0.55$-0.54$-0.70$-0.21$0.03$-0.52
Net margin-1121.6%-546.1%-245.9%-12.3%-100.7%-213.8%-91.7%-24.3%3.2%-109.9%
ROIC——-583.8%-24.4%-106.0%-44.5%0.7%0.7%2.4%-31.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Innate Pharma SA pay a dividend?

Not currently.

Is Innate Pharma SA a good stock to buy?

We do not give buy or sell advice. Innate Pharma SA scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.